Physician profile
Lyn E Tangen
NPI 1417068131
$1,350.00
in general payments reported to CMS, 2019-2025
15 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $63.82 · 2021: $87.75 · 2022: $220 · 2023: $169 · 2024: $194 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.55 | 2019-2025 | |
| Biom'Up Sa | $196.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.80 | 2020-2025 | Eohilia, Entyvio, Gattex |
| Daiichi Sankyo INC. | $120.10 | 2019-2024 | Injectafer |
| Ethicon US, LLC | $116.02 | 2022-2024 | Harmonic, Stratafix, Enseal X1 |
| Cook Biotech Incorporated | $110.65 | 2023 | Biodesign |
| Exact Sciences Corporation | $89.86 | 2025 | The Cologuard Plus Collection Kit |
| Qol Medical, LLC | $51.32 | 2022-2025 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.14 | 2019-2020 | |
| Reprise Biomedical, INC. | $42.35 | 2025 | Miro3d |
| Merck Sharp & Dohme LLC | $34.91 | 2020-2025 | Bridion |
| Sandoz INC. | $24.50 | 2025 | Hyrimoz |
| Ucb, INC. | $23.98 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.65 | 2022 | |
| Organon LLC | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyn Tangen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.